drugset / Trial / NCT04829123
The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects
RandomizedSequentialQuadruple-blindTreatment
Summary
A Phase 1, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of HEC88473 in healthy subjects
Timeline
- Start
- 2021-05-14
- Primary completion
- 2022-03-02
- Completion
- 2022-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HEC88473 | Protein / enzyme biologic | 0.5 mg | Subcutaneous |
| Subject | HEC88473 | Protein / enzyme biologic | 1.7 mg | Subcutaneous |
| Subject | HEC88473 | Protein / enzyme biologic | 5.1 mg | Subcutaneous |
| Subject | HEC88473 | Protein / enzyme biologic | 10.2 mg | Subcutaneous |
| Subject | HEC88473 | Protein / enzyme biologic | 17 mg | Subcutaneous |
| Subject | HEC88473 | Protein / enzyme biologic | 25.5 mg | Subcutaneous |
| Subject | HEC88473 | Protein / enzyme biologic | 34 mg | Subcutaneous |
| Subject | HEC88473 | Protein / enzyme biologic | 44.2 mg | Subcutaneous |